CureAge Therapeutics

CureAge Therapeutics develops genetic medicines for peripheral nerve disorders, initially targeting neurofibromatosis type 1 (NF1).

Its investigational platform uses locally delivered lipid nanoparticles to carry genetic material into Schwann cells, aiming to restore NF1 gene function and address surrounding tumour cells.

Founded in 2024 through a collaboration between the Children's Tumor Foundation and Deep Science Ventures, the company is evaluating its lead approach in preclinical models.